Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.

9 Dec 2009

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.

9 Dec 2009

AHS annual meeting focuses on myeloma, says IMF

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians— says a large number of abstracts – nearly a quarter of the presentations submitted this year to the annual meeting of the American Society of Hematology (ASH) were for myeloma, with one being presented at the prestigious plenary session.

9 Dec 2009

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376).

9 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

Immune-boosting drug: A new way for improving cancer treatment

Stimulating the body's own immune system to fight cancer offers new treatment opportunities for cancer patients, and scientists have made the first step towards finding existing drugs that could help.

9 Dec 2009

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Allos Therapeutics, Inc. today reported a new analysis of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

7 Dec 2009

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

ZIOPHARM Oncology prices public offering of 15,484,000 shares of its common stock

ZIOPHARM Oncology, Inc. announced the pricing of its previously announced underwritten public offering of 15,484,000 shares of its common stock and warrants to purchase 7,742,000 shares of its common stock at a public offering price of $3.10 per unit.

4 Dec 2009

ZIOPHARM Oncology begins public offering of common stock

ZIOPHARM Oncology, Inc. announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-lead managers for the offering.

4 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

The debate on how to select patients who will respond best to costly drug treatments for aggressive breast cancer now favors fluorescence in situ hybridization (FISH) to measure the HER-2 receptor found in human breast tumors, according to a leading pathologist presenting at the Association for Molecular Pathology annual meeting.

20 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

New radical approach to test chemo drugs for potential toxic effects

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects.

19 Nov 2009

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

11 Nov 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology(TM) for Breast Cancer discourages prophylactic mastectomy in women except for those considered high risk.

29 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Cyclophosphamide News and Research

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

AHS annual meeting focuses on myeloma, says IMF

Memgen announces positive clinical data of ISF35 with chemotherapy

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Immune-boosting drug: A new way for improving cancer treatment

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Researchers explore optimal induction therapies for managing blood cancer

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

ZIOPHARM Oncology prices public offering of 15,484,000 shares of its common stock

ZIOPHARM Oncology begins public offering of common stock

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

New radical approach to test chemo drugs for potential toxic effects

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News